Dogwood Therapeutics (DWTX) Other financing activities (2021 - 2026)
Dogwood Therapeutics (DWTX) posted quarterly Other financing activities of $132.0 for Q1 2026, up 100.15% quarter-over-quarter from -$85995.0 in Q4 2022.
Dogwood Therapeutics (DWTX) Other financing activities (2021 - 2026) Analysis & Trends
Dogwood Therapeutics (DWTX) has reported Other financing activities for 3 consecutive years, with $132.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other financing activities changed N/A year-over-year to $132.0; the TTM figure through Mar 2026 stood at -$578591.0 (changed N/A YoY), while the FY2022 annual figure was $4.5 million, up 1621.38% from the prior year.
- Other financing activities improved to $132.0 in Q1 2026 per DWTX's latest filing, from -$85995.0 in the prior quarter.
- Across five years, Other financing activities topped out at $132.0 in Q1 2026 and bottomed at -$85995.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Dogwood Therapeutics | 84.98 Mn | 84.98 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 132.00 |
| Mar 31, 2026 | 132.00 |
| Dec 31, 2022 | -85,995.00 |
| Dec 31, 2022 | -85,995.00 |
| Dec 31, 2021 | -492,728.00 |
| Dec 31, 2021 | -492,728.00 |
| Mar 31, 2021 | 197,562.00 |
| Mar 31, 2021 | 197,562.00 |